AstraZeneca's Atacand Adds ACE Inhibitor Combo Claim For Heart Failure
This article was originally published in The Pink Sheet Daily
Executive Summary
Angiotensin receptor blocker is the first in its class to gain the indication. FDA's approval is in line with the Cardio-Renal Advisory Committee's unanimous recommendation in February.
You may also be interested in...
Diovan Clears FDA For Post-Myocardial Infarction Mortality Reduction
Agency also removes restriction in labeling limiting heart failure indication to patients intolerant of ACE inhibitors.
Diovan Clears FDA For Post-Myocardial Infarction Mortality Reduction
Agency also removes restriction in labeling limiting heart failure indication to patients intolerant of ACE inhibitors.
AstraZeneca's Atacand Heart Failure Indication Clears FDA Ahead Of Cmte. Review
The agency approves candesartan for treatment of heart failure to reduce cardiovascular mortality and hospitalizations. The angiotensin receptor blocker is the first product in its class to receive the claim. Approval comes two days before an FDA advisory panel review.